Polatuzumab vedotin-piiq
Polatuzumab vedotin-piiq (pronunciation: poe-lat-oo-ZOO-mab ve-DOE-tin PEE-ik) is a monoclonal antibody conjugated with a chemotherapeutic agent used in the treatment of certain types of non-Hodgkin lymphoma (NHL).
Etymology
The name "Polatuzumab vedotin-piiq" is derived from the components of the drug. "Polatuzumab" is the name of the monoclonal antibody, "vedotin" refers to the chemotherapeutic agent, and "piiq" is a suffix used by the World Health Organization (WHO) to denote a specific type of antibody-drug conjugate.
Usage
Polatuzumab vedotin-piiq is used in combination with bendamustine and a rituximab product to treat adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), a type of non-Hodgkin lymphoma, who have received at least two prior therapies.
Mechanism of Action
Polatuzumab vedotin-piiq works by binding to the CD79b protein found on the surface of B-cells, including malignant B-cells in NHL. Once bound, the drug is internalized by the cell, where the chemotherapeutic agent is released to kill the cell.
Side Effects
Common side effects of polatuzumab vedotin-piiq include low blood cell counts, fatigue, diarrhea, and nausea. Serious side effects can include peripheral neuropathy, infections, and infusion-related reactions.
Related Terms
- Monoclonal antibody
- Chemotherapeutic agent
- Non-Hodgkin lymphoma
- Bendamustine
- Rituximab
- Diffuse large B-cell lymphoma
- CD79b protein
External links
- Medical encyclopedia article on Polatuzumab vedotin-piiq
- Wikipedia's article - Polatuzumab vedotin-piiq
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski